Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical Industry Adopting Lifecycle Models for Process Validation

This article was originally published in The Gold Sheet

Executive Summary

The pharmaceutical industry is incorporating the lifecycle approach to process validation – and seeing some of its benefits after initial misgivings – while an FDA official discussed the elements of a robust process validation program and consequences when these are not in place. Industry is developing separate guidance on designing process validation studies for biotechnological drugs.

Advertisement

Related Content

Pharmaceutical lndustry Proposes Ideas for Number of Batches, Monitoring Production
Opportunities to Statistically Mine PAT Data for Release Testing Explored
FDA Guidance Exempts Legacy Products from Early Stage Process Validation; Endorses Use of PAT

Topics

Advertisement
UsernamePublicRestriction

Register

PS000725

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel